Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Micro-Probe Corporation (AKA: Microprobe~Saigene~Epoch Pharmaceuticals~Epocj Bioscience)
Profile last edited on: 9/21/2006      CAGE:       UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
----
First Award
1986
Latest Award
1996
Program Status
Inactive (Acquired)
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1725 220th Street SE Suite 104
Bothell, WA 98021
   (425) 485-8566
   N/A
   N/A
Location: Single
Congr. District: 01
County: Snohomish

Public Profile

In December of 2004, Micro-Probe Corporation (Epoch Bioscience) was acquired by Nanogen, Inc. (Nasdaq: NGEN), another SBIR firm. Originally known as Micro-Probe Corporation also (Microprobe), in 1998 firm name changed to Saigene. From that point, having sold most of its diagnostics business to Becton-Dickinson & Co, all SBIR awards were made to the firm Epoch Pharmaceuticals which then was recently renamed Epoch Bioscience (NASDAQ).

Extent of SBIR involvement

User Avatar
Phase I Awards
21
Phase II Awards
9
Conversion Rate
42.86%
Phase I Dollars
$1,185,174
Phase II Dollars
$4,276,149
Total Awarded
$5,461,323

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
25-49

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
1996 1 NIH $97,762
Project Title: Antibiotic Susceptibility Testing For Oral Bacteria
1995 1 NIH $98,307
Project Title: DNA Probe Detection of Oral Spirochetes
1995 1 NIH $93,147
Project Title: Biochemistry of Oligomer/Pyrroloindole Conjugates
1995 2 NIH $510,832
Project Title: Genetic and metabolic probes of antibiotic resistance
1993 2 NIH $550,000
Project Title: Nuclear targeting of oligonucleotide-peptide conjugates

Key People / Management

  Gerard Cangelosi

  Paul Haydock

  Rich B Meyer

  Charles R Petrie

  Dennis E Schwartz

  Diana K Sheiness

  Nick Vermeulen

Company News

There are no news available.